Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Operating Margin (2016 - 2025)

Protalix BioTherapeutics has reported Operating Margin over the past 16 years, most recently at 3.68% for Q4 2025.

  • Quarterly results put Operating Margin at 3.68% for Q4 2025, down 2654.0% from a year ago — trailing twelve months through Dec 2025 was 2.23% (down 387.0% YoY), and the annual figure for FY2025 was 2.23%, down 387.0%.
  • Operating Margin for Q4 2025 was 3.68% at Protalix BioTherapeutics, down from 11.94% in the prior quarter.
  • Over the last five years, Operating Margin for PLX hit a ceiling of 58.22% in Q2 2023 and a floor of 142.62% in Q2 2021.
  • Median Operating Margin over the past 5 years was 20.14% (2022), compared with a mean of 31.65%.
  • Biggest five-year swings in Operating Margin: crashed -12219bps in 2021 and later skyrocketed 15900bps in 2024.
  • Protalix BioTherapeutics' Operating Margin stood at 66.74% in 2021, then soared by 57bps to 28.95% in 2022, then tumbled by -370bps to 136.14% in 2023, then soared by 117bps to 22.86% in 2024, then crashed by -116bps to 3.68% in 2025.
  • The last three reported values for Operating Margin were 3.68% (Q4 2025), 11.94% (Q3 2025), and 7.48% (Q2 2025) per Business Quant data.